Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Policy & Politics

Lawmakers Attack Cost of New Hepatitis Drug

March 26, 2014

This article was reported by The New York Times.

The New York Times reported that three US representatives are calling for the pharmaceutical company Gilead to justify the hefty cost of its new hepatitis C drug, Sovaldi. The lawmakers, all Democrats on the House Energy and Commerce Committee, wrote an open letter to Gilead to find out why the drug, which is touted as a breakthrough in treatment for hepatitis C, is priced at $1,000 per pill. Critics argue that the high cost, which insurance companies and state Medicaid programs are not yet willing to universally cover, puts it out of reach for most Americans.

View Full Article


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

 
See Also
More News and Research on Sovaldi (Sofosbuvir)

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

 

Advertisement